Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial

BACKGROUND: Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigated TNT-D as a surrogate endpoint (SE) for overall survival (OS) in previously untreated advanced melanoma patients. METHODS: Patient-leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Branchoux, S., Sofeu, C.L., Gaudin, A.-F., Kurt, M., Moshyk, A., Italiano, A., Bellera, C., Rondeau, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693416/
https://www.ncbi.nlm.nih.gov/pubmed/34929616
http://dx.doi.org/10.1016/j.esmoop.2021.100340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693416/
https://www.ncbi.nlm.nih.gov/pubmed/34929616
http://dx.doi.org/10.1016/j.esmoop.2021.100340

Ejemplares similares